Merus NV (MRUS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Merus NV (MRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8027
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Merus NV (Merus) is a clinical-stage immuno-oncology company that discovers and develops human bispecific antibody therapeutics for the treatment of cancer. The company’s pipeline antibody candidates are intended for the treatment of breast cancer, ovarian cancer, colorectal cancer, acute myeloid leukemia and other solid tumors. Merus develops its product candidates based on its proprietary technology platform biclonics, a bispecific, full length human IgG antibodies. The company has collaboration with Incyte Corporation, to develop preclinical bispecific antibody designed to bind to PD-L1. Merus is headquartered in Utrecht, the Netherlands.

Merus NV (MRUS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merus NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Merus NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Merus NV, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Merus Raises USD55.8 Million in Venture Financing 12
Merus Raises USD46.4 Million in First Tranche of Series C Financing 13
Merus Raises US$42 Million In Extended Series B Financing 15
Private Equity 17
Biotechnology Value Fund to Invest USD55.8 million in Merus 17
Partnerships 18
Integral Molecular Enters into Agreement with Merus 18
Merus Enters into Research Agreement with Vall d’Hebron Institute of Oncology 19
Merus Enters into Research Agreement with Institute for Research in Biomedicine 20
Merus Enters into Co-Development Agreement with Institut Gustave Roussy 21
Licensing Agreements 22
Ono Pharma Enters into Licensing Agreement with Merus 22
Simcere Pharma to Enter into Licensing Agreement with Merus 23
Incyte Enters into Licensing Agreement with Merus 24
Ono Pharma Exercises Option for Licensing Agreement with with Merus 26
ProBioGen Enters into Licensing Agreement with Merus 27
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 28
Equity Offering 29
Merus Raises USD80 Million in Private Placement 29
Merus Announces Partial Exercise of Underwriter’s Option for IPO for USD61.39 Million 30
Merus NV – Key Competitors 32
Merus NV – Key Employees 33
Merus NV – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 10, 2018: Merus announces financial results for the second quarter 2018 & mid-year operating results 35
Jul 26, 2018: Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 37
Apr 26, 2018: Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017 39
Nov 30, 2017: Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights 42
Sep 19, 2017: Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress 44
Jul 11, 2017: Merus Announces First Quarter 2017 Financial Results And Mid-Year Operating Results 45
Apr 28, 2017: Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments 47
Corporate Communications 49
Sep 27, 2018: Merus strengthens team with key appointments 49
Aug 22, 2018: Merus announces formation of a scientific advisory board 50
Legal and Regulatory 51
Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron’s Petition to Rehear the Panel’s Decision Affirming Merus’ Inequitable Conduct Claim Against Regeneron 51
Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron 52
Product News 53
04/20/2017: Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Merus NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merus NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merus NV, Deals By Therapy Area, 2012 to YTD 2018 9
Merus NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Merus Raises USD55.8 Million in Venture Financing 12
Merus Raises USD46.4 Million in First Tranche of Series C Financing 13
Merus Raises US$42 Million In Extended Series B Financing 15
Biotechnology Value Fund to Invest USD55.8 million in Merus 17
Integral Molecular Enters into Agreement with Merus 18
Merus Enters into Research Agreement with Vall d’Hebron Institute of Oncology 19
Merus Enters into Research Agreement with Institute for Research in Biomedicine 20
Merus Enters into Co-Development Agreement with Institut Gustave Roussy 21
Ono Pharma Enters into Licensing Agreement with Merus 22
Simcere Pharma to Enter into Licensing Agreement with Merus 23
Incyte Enters into Licensing Agreement with Merus 24
Ono Pharma Exercises Option for Licensing Agreement with with Merus 26
ProBioGen Enters into Licensing Agreement with Merus 27
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 28
Merus Raises USD80 Million in Private Placement 29
Merus Announces Partial Exercise of Underwriter’s Option for IPO for USD61.39 Million 30
Merus NV, Key Competitors 32
Merus NV, Key Employees 33
Merus NV, Subsidiaries 34

List of Figures
Merus NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merus NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Merus NV (MRUS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • APR Applied Pharma Research SA-医療機器分野:企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Panda Restaurant Group Inc:企業の戦略・SWOT・財務情報
    Panda Restaurant Group Inc - Strategy, SWOT and Corporate Finance Report Summary Panda Restaurant Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Oltchim SA (OLT):企業の財務・戦略的SWOT分析
    Summary Oltchim SA (Oltchim) is a chemical company that manufactures and markets petrochemical products. The company offers inorganic, macro molecular and organic synthesis products. Its inorganic products include caustic soda, liquid chlorine, hydrochloric acid and sodium hypochlorite. Oltchim's ma …
  • Nipro Corp (8086):医療機器:M&Aディール及び事業提携情報
    Summary Nipro Corp (Nipro) manufactures, develops and markets pharmaceuticals, medical equipment and functional materials (including glass, rubber and plastic). The company’s products include renal products, interventional and anesthesiology products, injection and infusion products, cardiopulmonary …
  • Trovagene Inc (TROV)-製薬・医療分野:企業M&A・提携分析
    Summary Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests t …
  • Sunflower Electric Power Corp:企業の戦略的SWOT分析
    Sunflower Electric Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Flex Ltd (FLEX):電力:M&Aディール及び事業提携情報
    Summary Flex Ltd (Flex) provides design, engineering, manufacturing, and supply chain services to electronics original equipment manufacturers. The company, through its Sketch-to-Scale concept, provides concept design, prototype creation, intellectual property protection, new product introduction, a …
  • Lexmark International Inc:医療機器:M&Aディール及び事業提携情報
    Summary Lexmark International Inc (Lexmark) a subsidiary of Ninestar Corp., provider of imaging and printing solutions. It manufactures, develops and supplies printing and imaging solutions, managed print services, device management, document workflow, business process and content management solutio …
  • Tarsa Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Tarsa Therapeutics Inc (Tarsa) develops therapies for the treatment and prevention of osteoporosis and other bone related diseases. The company develops TBRIA, an oral formulation of calcitonin, a peptide hormone that inhibits bone resorption, which is used for the treatment of postmenopausa …
  • China Chemical & Pharmaceutical Co Ltd (1701):企業の財務・戦略的SWOT分析
    China Chemical & Pharmaceutical Co Ltd (1701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Balaji Amines Ltd (BALAMINES):企業の財務・戦略的SWOT分析
    Balaji Amines Ltd (BALAMINES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Thryv Holdings Inc (THRY):企業の財務・戦略的SWOT分析
    Thryv Holdings Inc (THRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Mitsubishi International Food Ingredients, Inc.:企業の戦略・SWOT・財務情報
    Mitsubishi International Food Ingredients, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi International Food Ingredients, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • My Health Direct Inc:医療機器:M&Aディール及び事業提携情報
    Summary My Health Direct Inc (MHD) is a healthcare technology company that offers web-based solutions for the management of healthcare appointments. The company helps clients in achieving incremental revenue growth and real-time cost containment savings. It offers products such as consumer direct an …
  • Enable Midstream Partners LP (ENBL):企業の財務・戦略的SWOT分析
    Enable Midstream Partners LP (ENBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Nuvo Pharmaceuticals Inc (NRI)-製薬・医療分野:企業M&A・提携分析
    Summary Nuvo Pharmaceuticals Inc (Nuvo), formerly known as Nuvo Research Inc is a drug company that offers topical pain products and technologies. The company’s product portfolio includes pennsaid, pennsaid 2%, and heated lidocaine and tetracaine patches. Its products deliver drugs topically into an …
  • NeuroVive Pharmaceutical AB (NVP):企業の財務・戦略的SWOT分析
    Summary NeuroVive Pharmaceutical AB (NeuroVive), formerly NeuroPharma i Sverige AB focuses on the research and development of mitochondrial therapies. The company’s programs include NeuroSTAT, a clinical phase II drug candidate for the prevention of traumatic brain injury; and phase I KL1333, a nove …
  • Suzuken Co Ltd (9987):企業の財務・戦略的SWOT分析
    Suzuken Co Ltd (9987) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • HemaCare Corp (HEMA)-医療機器分野:企業M&A・提携分析
    Summary HemaCare Corp (HemaCare) is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, bone marrow and cord blood. It spans its expertise in isolations, custom cell collections and testing of pr …
  • Goodwin Biotechnology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Goodwin Biotechnology Inc (GBI), a subsidiary of Wallace Pharmaceuticals Pvt Ltd is a healthcare company that develops and manufactures vaccines, monoclonal antibodies, recombinant proteins and bioconjugates. The company offers cell culture, purification, bioconjugation, biosimilars, aseptic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆